Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/DGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovation in renal cell carcinoma (RCC) has brought new opportunities to improve patient outcomes through personalized medicine. With multiple FDA approvals and promising agents being explored in a variety of settings, multitargeted TKIs and immune checkpoint inhibitors have earned their place in cancer care plans either as guideline-recommended therapy or through clinical trial enrollment. In this activity, which was based on a recent live event, a panel of expert oncologists combines a concise overview of essential research on approved and emerging RCC treatments with discussion of real-life patient cases to provide guidance on integrating validated strategies into everyday patient care. Learn how patient-, disease-, and treatment-specific factors affect therapeutic selection and sequencing—including when to consider adjuvant therapy, which patients may benefit from immunothe

Go online to PeerView.com/EHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs). Upon completion of this activity, participants should be better able to: Apply current hyperlipidemia treatment

Go online to PeerView.com/YAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials. As such, clinicians must remain up to date with the latest data on the rationale for their use and trial findings on the efficacy, safety, and tolerability of this promising line of treatment. At a recent PeerView live event, MS experts shared relevant stories from their practice to highlight the rationale for the use of BTK inh

Go online to PeerView.com/ERY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hundreds of thousands of organ transplant recipients living in the United States, who must take immunosuppressive medication, are at an increased risk of COVID-19 infection. Tixagevimab co-packaged with cilgavimab has lost its emergency use authorization as prevention for immunocompromised patients because of its lack of efficacy against newer variants. In the absence of prevention agents (other than vaccines) and because the prevention of COVID-19 is shifting to a more personalized, patient-specific approach, the complexity of clinical decision-making has increased. Additionally, patients may face barriers in obtaining COVID-19 prevention. In this activity, based on a recent live symposium, expert faculty and a patient advocate discuss strategies to improve the uptake of COVID-19 prevention and increase patient and clinician engagement and how to develop a plan to customize COV

Go online to PeerView.com/GUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent symposium held during the 2023 ASCO Annual Meeting, leading experts guide you through the winning era of immunotherapy in melanoma. Through a series of linked lectures and debates, the panel discusses the integration of modern immunotherapy combination and sequential options in advanced disease and considers options for patients progressing on prior immunotherapy. They also examine new developments with immunotherapy in the adjuvant and neoadjuvant settings. Upon completion of this activity, participants should be better able to: Discuss current guidelines, efficacy, and safety data surrounding the use of immunotherapy in melanoma as neoadjuvant or adjuvant therapy in resectable disease or as part of novel combinatorial or sequential approaches for unresectable disease; Craft team-based treatment plans that include immunotherapy for resectable

Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decis

Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommen

Go online to PeerView.com/TNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about non-factor therapies in the prophylactic management of hemophilia? Test your knowledge and earn credit, as you get the latest evidence and expert guidance on integrating these therapies into individualized management plans for adult and pediatric patients with hemophilia. Upon completion of this activity, participants should be better able to: Discuss current unmet needs and barriers to optimal prophylaxis of hemophilia; Summarize the MOAs and latest safety/efficacy evidence supporting the use of novel and emerging antibody and siRNA therapies for the prophylaxis of HA and HB; Develop personalized prophylactic regimens with novel and emerging antibody and siRNA therapies, including in the context of clinical trials, for the management of HA and HB; and Manage practical aspects of care when using novel non-factor agents, including dosing/scheduling, pat

Go online to PeerView.com/QGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities. This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety. Upon completion of this activity, participants should be better able to: Recognize the individual, clinical, and economic burdens of OAB

Go online to PeerView.com/JQE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have transformed the frontline management of recurrent/metastatic head and neck cancer (HNC)—but how can oncology professionals build on that foundation to expand the therapeutic applications of immunotherapy in HNC? This “MasterClass & Case Forum” activity, taken from a recent live event, features a panel of leading HNC experts sharing case-based insights on clinical decision-making with immunotherapy in recurrent/metastatic disease and beyond. Developed in collaboration with the Head and Neck Cancer Alliance (HNCA), each case-centric session also features the latest evidence on established and emerging immune-based treatments, combinational and sequential approaches, and the potential of checkpoint blockade in resectable and locally advanced disease. Upon completion of this activity, participants should be better able to: Cite the latest clinic

Go online to PeerView.com/NXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy based on molecular findings. In this activity, our expert faculty will provide updates on evolving evidence-based practice standards and discuss how to effectively integrate the latest treatment advances into practice. You will learn to identify appropriate baseline diagnostic testing to inform the selection of targeted therapy for your patients with gastrointestinal cancers. Our experts will also introduce the latest evidence supporting relevant, novel strategies and explain when to initiate these agents in comparison with conventional treatment. Upon completion of this activity, participants should be better able to: Recognize current evidence supporting molecular

Go online to PeerView.com/TAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibodies, tyrosine kinase inhibitors, cellular therapy, and modern asparaginases, such as pegylated Escherichia coli and Erwinia chrysanthemi compounds have vastly improved treatment plans for pediatric and adolescent and young adult (AYA) populations with acute lymphoblastic leukemia (ALL). The approval of newer Erwinia formulations has expanded the therapeutic foundation on which clinicians can build effective strategies to address challenges such as asparaginase discontinuation due to hypersensitivity or silent inactivation. This "Clinical Consults" activity focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric and AYA ALL therapy. Watch experts provide guidance on the modern use of asparaginase therapy and share tactics for addressing real-world barriers to effective care, including hypersensitivity, silent inactivation

Go online to PeerView.com/MWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, Dr. Jessica Ailani reviews the latest data on therapies for acute and preventive management of migraine, with a focus on personalized treatment. A patient interview and 3D animation are also part of this engaging video program. Upon completion of this activity, participants should be better able to: Apply safety and efficacy data related to new acute migraine therapies in clinical decision-making, taking into account patient-reported outcomes; Employ evidence-based prevention strategies for patients with migraine; and Implement individualized treatment plans for patients with migraine.

Go online to PeerView.com/SND860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–cystic fibrosis bronchiectasis (NCFBE) is a long-term respiratory condition with a significant impact on quality of life, morbidity, mortality, and use of healthcare resources. Recurrent infections, persistent cough, sputum production, and exacerbations can lead to disease worsening, making early diagnosis of paramount importance. Healthcare professionals involved in the diagnosis of patients with bronchiectasis must be aware of the various etiologies and CT features associated with NCFBE. This question-based educational activity will review these topics and make it easy to claim your CME/MOC credit. Upon completion of this activity, participants should be better able to: Use risk factors, signs and symptoms, testing, and imaging to facilitate accurate and prompt diagnosis and intervention to minimize progression of NCFBE; Describe underlying pathophysiologic mechanisms, inc

Go online to PeerView.com/QFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging activity, which is based on a pre-conference workshop held at OMA 2023, experts in obesity management aim to change misperceptions about obesity and explain best practices for treating this chronic condition, which include the importance of anti-obesity medications (AOMs) in achieving individualized weight goals and improving overall health outcomes by reducing the risk and progression of obesity-related comorbidities. Upon completion of this activity, participants should be better able to: Initiate appropriate, unbiased, and nonjudgmental conversations with patients about obesity acknowledging it as a chronic, treatable disease rather than a result of personal irresponsibility; Compare the efficacy and safety profiles of current and emerging anti-obesity medications and their potential to support weight loss efforts and minimize the impact of obesity-related co

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy a

Go online to PeerView.com/RFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent developments targeting the RAS/MAPK signaling pathway have led to the first approved MEK inhibitor for the treatment of pediatric patients with symptomatic, inoperable PNs. To help lay the foundation of personalized NF1 care, this activity—based on a live event at the recent ASPHO meeting—features expert panelists sharing real-world cases to illustrate the collaborative management of NF1 tumors with highly efficacious targeted agents. The case-based conversations cover the diagnostic-treatment arc of NF1-PNs, culminating with tips and tactics arising from the clinical experience with MEK inhibitors—and going beyond to include insights on targeted strategies in other NF1 tumor settings. Watch now to start building your personalized management on a bedrock of solid science! Upon completion of this activity, participants should be better able to: Summarize current evidence a

Go online to PeerView.com/SGZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mucus plugging contributes to airway obstruction and death in acute asthma and is increasingly being recognized as a significant contributory factor to persistent, severe asthma. Pulmonologists, allergy and immunology specialists, and other healthcare professionals need to be aware of these latest insights into the pathophysiology of severe asthma to optimally care for their patients. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Dr. Monica Tang will show learners how to identify the presence of airway mucus plugging on HRCT, and she will review the latest evidence with regard to mucus plugging treatment. Upon completion of this activity, participants should be better able to: Explain the role of mucus plugging as a contributory factor to airway

Go online to PeerView.com/NDY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM! Upon completion of this activity, participants should be better able to: Describe the me

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don’t forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate